Patient characteristics
| Characteristics . | All . | Telomere-length quartiles . | ||||
|---|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | P . | ||
| Telomeres length, T:S mean | 1.09 | 0.64 | 0.94 | 1.18 | 1.62 | 10−4 |
| Age-adjusted telomeres length, T:S mean (range) | −0.16 (−1.08 to 1.85) | −0.61 (−1.08 to −0.42) | −0.30 (−0.42 to −0.19) | −0.08 (−0.19 to 0.02) | 0.35 (0.03 to 1.85) | 10−4 |
| Patients, no. (%) | 178 | 45 (25) | 44 (25) | 45 (25) | 44 (25) | |
| Recipient sex, M/F | 101/77 | 26/19 | 26/18 | 28/17 | 21/23 | .55 |
| Donor sex, M/F | 95/83 | 24/21 | 27/17 | 23/22 | 21/23 | .62 |
| Mean age, y (SD) | 31.8 | 32.4 | 33.3 | 30.7 | 30.8 | .85 |
| CMV recipient, Neg/Pos | 63/114 | 17/28 | 18/26 | 15/29 | 13/31 | .71 |
| CMV donor, Neg/Pos | 80/95 | 18/27 | 19/25 | 21/23 | 22/22 | .78 |
| Stem cell source, BM/PBSC | 128/50 | 27/18 | 32/12 | 35/10 | 34/10 | .21 |
| Conditioning regimen* | ||||||
| TBI ≥ 12 Gy, no. (%) | 67 | 17 (25) | 15 (22) | 19 (29) | 16 (24) | .82 |
| BU-based regimen, no. (%)† | 103 | 28 (27) | 27 (26) | 23 (23) | 25 (24) | .82 |
| Malignant diseases, no. (%)‡ | ||||||
| AML in CR1§ | 46 | 17 (37) | 7 (15) | 8 (17) | 14 (31) | .11 |
| Intermediate-I | 20 | 7 (35) | 5 (25) | 4 (20) | 4 (20) | .36 |
| Intermediate-II | 9 | 3 (34) | 0 | 2 (22) | 4 (44) | .36 |
| Adverse | 14 | 7 (50) | 1 (11) | 1 (11) | 4 (28) | .36 |
| ALL in CR1 | 32 | 8 (25) | 7 (22) | 9 (28) | 8 (25) | .97 |
| Chronic myelogenous leukemia | 20 | 6 (30) | 9 (45) | 4 (20) | 1 (5) | .08 |
| Myelodysplastic syndrome | 13 | 5 (38) | 3 (23) | 2 (16) | 3 (23) | — |
| Disease stage, no. (%) | ||||||
| Nonmalignant | 25 | 0 | 5 | 7 | 13 | .002 |
| Malignant early-stage | 93 | 27 | 22 | 20 | 24 | .002 |
| Malignant advanced-stage | 60 | 18 | 17 | 18 | 7 | .002 |
| Characteristics . | All . | Telomere-length quartiles . | ||||
|---|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | P . | ||
| Telomeres length, T:S mean | 1.09 | 0.64 | 0.94 | 1.18 | 1.62 | 10−4 |
| Age-adjusted telomeres length, T:S mean (range) | −0.16 (−1.08 to 1.85) | −0.61 (−1.08 to −0.42) | −0.30 (−0.42 to −0.19) | −0.08 (−0.19 to 0.02) | 0.35 (0.03 to 1.85) | 10−4 |
| Patients, no. (%) | 178 | 45 (25) | 44 (25) | 45 (25) | 44 (25) | |
| Recipient sex, M/F | 101/77 | 26/19 | 26/18 | 28/17 | 21/23 | .55 |
| Donor sex, M/F | 95/83 | 24/21 | 27/17 | 23/22 | 21/23 | .62 |
| Mean age, y (SD) | 31.8 | 32.4 | 33.3 | 30.7 | 30.8 | .85 |
| CMV recipient, Neg/Pos | 63/114 | 17/28 | 18/26 | 15/29 | 13/31 | .71 |
| CMV donor, Neg/Pos | 80/95 | 18/27 | 19/25 | 21/23 | 22/22 | .78 |
| Stem cell source, BM/PBSC | 128/50 | 27/18 | 32/12 | 35/10 | 34/10 | .21 |
| Conditioning regimen* | ||||||
| TBI ≥ 12 Gy, no. (%) | 67 | 17 (25) | 15 (22) | 19 (29) | 16 (24) | .82 |
| BU-based regimen, no. (%)† | 103 | 28 (27) | 27 (26) | 23 (23) | 25 (24) | .82 |
| Malignant diseases, no. (%)‡ | ||||||
| AML in CR1§ | 46 | 17 (37) | 7 (15) | 8 (17) | 14 (31) | .11 |
| Intermediate-I | 20 | 7 (35) | 5 (25) | 4 (20) | 4 (20) | .36 |
| Intermediate-II | 9 | 3 (34) | 0 | 2 (22) | 4 (44) | .36 |
| Adverse | 14 | 7 (50) | 1 (11) | 1 (11) | 4 (28) | .36 |
| ALL in CR1 | 32 | 8 (25) | 7 (22) | 9 (28) | 8 (25) | .97 |
| Chronic myelogenous leukemia | 20 | 6 (30) | 9 (45) | 4 (20) | 1 (5) | .08 |
| Myelodysplastic syndrome | 13 | 5 (38) | 3 (23) | 2 (16) | 3 (23) | — |
| Disease stage, no. (%) | ||||||
| Nonmalignant | 25 | 0 | 5 | 7 | 13 | .002 |
| Malignant early-stage | 93 | 27 | 22 | 20 | 24 | .002 |
| Malignant advanced-stage | 60 | 18 | 17 | 18 | 7 | .002 |
T:S indicates telomere to single copy gene ratio; PBSC, peripheral blood stem cell; Neg, negative; Pos, positive; TBI, total body irradiation; BU, busulfan; AML, acute myeloid leukemia; CR, complete remission; and ALL, acute lymphoid leukemia.
Eight patients received cyclophosphamide in the context of severe aplastic anemia.
Fifty patients received busulfan orally while 53 received it intravenously. The distribution as well as outcomes posttransplantation were not different among quartiles if the busulfan was given orally or intravenously.
Twenty-two patients with acute leukemia did not receive transplants in first CR. Other malignant diseases included lymphoma (n = 8), myeloproliferative disorders different from CML (n = 7), and myeloma (n = 5).
No patients with AML received transplants in CR1 in case of favorable risk.